1305208-33-6

Basic information

• Product Name: 1H-Indazole, 6-broMo-4-(phenylMethoxy)-
• Synonyms: 1H-Indazole, 6-broMo-4-(phenylMethoxy)-;4-(benzyloxy)-6-bromo-1H-indazole
• CAS NO: 1305208-33-6
• Molecular Formula: C14H11BrN2O
• Molecular Weight: 303.15394
• Mol File: 1305208-33-6.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Indazole, 6-broMo-4-(phenylMethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indazole, 6-broMo-4-(phenylMethoxy)-(1305208-33-6)
• EPA Substance Registry System: 1H-Indazole, 6-broMo-4-(phenylMethoxy)-(1305208-33-6)

Safety Data

• Hazardous Substances Data: 1305208-33-6(Hazardous Substances Data)

Usage

Indazole derivative

A heterocyclic compound with a five-membered ring and two nitrogen atoms

Bromine atom at the 6th position

Contributes to the compound's specific properties and reactivity

Phenylmethoxy group at the 4th position

Affects the compound's reactivity and properties

Use in organic synthesis and medicinal chemistry

As a building block for the synthesis of biologically active molecules and pharmaceuticals

Potential applications

In the development of new drug candidates and as a research tool in chemical biology.

Upstream product

• 537013-51-7 4-bromo-2,6-difluorobenzaldehyde 
• 461-96-1 3,5-difluorobromobenzene 

Relevant articles and documents

Discovery of 4-Aminoquinoline-3-carboxamide derivatives as potent reversible Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis

A structure-hopping strategy was applied to discover a series of novel 4-aminoquinoline-3-carboxamide derivatives as potent, reversible BTK inhibitors. Compared to the previously described cinnoline scaffold compounds, the 4-aminoquinoline analogues showed significantly improved drug-like properties, especially in their aqueous solubility. The most potent compound, 25, displayed a stronger inhibitory effect on both BTKWT (IC50 = 5.3 nM) and BTKC481S (IC50 = 39 nM). In a rodent collagen-induced arthritis model, compound 25 efficiently reduced paw swelling without a loss in body weight. On the basis of potency, drug-like properties, stability, and noncovalent mode of inhibition, our representative inhibitors could have a promising profile to be treatments for a wide range of autoimmune diseases.